An Open-Label Study of Oral NNZ-2591 in Pitt Hopkins Syndrome (PTHS-001)

Summary

A study of the safety, tolerability and pharmacokinetics of NNZ-2591 and measures of efficacy in children and adolescents with Pitt Hopkins Syndrome.

Timeline

Start

2022-10-14

Primary completion

2024-02-27

Completion

2024-05-03

Outcome

Met primary endpoint

release “today announced top-line results from its Phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS). Statistically significant” neurenpharma.com ↗

Drugs

Indications